Kenneth Tramposch

Kenneth Tramposch has over 20 years of experience in drug development and has been involved in the submission of many INDs and NDAs during his professional career in the pharmaceutical industry. One of Dr. Tramposch’s inventions at Bristol-Myers Squibb, for which he led the development team up to IND submission, was approved by the FDA in 1999 as a new drug and is currently marketed under the name Solage. At Pilot Therapeutics, he was responsible for the planning and execution of research and development activities and completed the development of the Company’s first product in 12 months. Kenneth Tramposch is the retired Associate Vice-President for Research and Associate Professor of Pharmacology and Toxicology at University at Buffalo.